Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 29 · inside the Ichimoku cloud · RSI 50 · MACD below its signal · 8% below its 52-week high
None of the 29 investors followed here reported a position in MBX.TO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MBX.TO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MBX.TO.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.3 | 9.1 | -4.2 | 13.0 | 3.8 | 11.1 | 0.0 | 0.0 | 3.3 | -1.6 | +32.6% | ||
| 2025 | 19.5 | -10.2 | -2.3 | -18.6 | -2.9 | -11.8 | 0.0 | -20.0 | 12.5 | -7.4 | 0.0 | -8.0 | −43.9% |
| 2024 | 0.0 | 2.6 | -7.5 | -5.4 | -8.6 | -6.2 | 13.3 | 11.8 | -10.5 | -5.9 | -3.1 | 32.3 | +5.1% |
| 2023 | -9.8 | -2.7 | 5.6 | 2.6 | 2.6 | -2.5 | -17.9 | 3.1 | -6.1 | -12.9 | 11.1 | 30.0 | −4.9% |
| 2022 | -18.1 | -20.6 | 11.1 | -11.7 | 5.7 | -10.7 | -2.0 | 10.2 | -5.6 | -2.0 | -8.0 | -10.9 | −50.6% |
| 2021 | 18.6 | 23.5 | -6.3 | 8.5 | -6.2 | -8.3 | 10.9 | 3.3 | 0.0 | 9.5 | 8.7 | 10.7 | +93.0% |
| 2020 | -4.0 | -16.7 | 20.0 | 37.5 | 3.0 | -2.9 | 0.0 | -18.2 | -3.7 | 46.2 | 5.3 | 7.5 | +72.0% |
| 2019 | 4.2 | 4.0 | -3.8 | 12.0 | 21.4 | -8.8 | -16.1 | -3.8 | -4.0 | 4.2 | -4.0 | 4.2 | +4.2% |
| 2018 | -3.2 | 0.0 | -6.7 | 14.3 | -3.1 | -3.2 | -13.3 | 3.8 | -7.4 | -16.0 | -9.5 | 26.3 | −22.6% |
| 2017 | 15.4 | -6.7 | -14.3 | 4.2 | 32.0 | -6.1 | -9.7 | 25.0 | 5.7 | -8.1 | 0.0 | -8.8 | +19.2% |
| 2016 | -15.6 | -7.4 | 12.0 | -3.6 | -11.1 | -8.3 | 27.3 | -3.6 | -11.1 | -4.2 | -4.3 | 18.2 | −18.8% |
| 2015 | -26.8 | -11.7 | 3.8 | 0.0 | -7.3 | -7.8 | -17.0 | 10.3 | -9.3 | -12.8 | -14.7 | 10.3 | −61.0% |
| 2014 | 194.1 | -4.0 | -20.8 | 0.0 | -2.6 | -5.4 | 25.7 | 4.5 | 30.4 | 13.3 | 22.1 | -1.2 | +382.4% |
| 2013 | -11.5 | -4.3 | 4.5 | -21.7 | -5.6 | 23.5 | -4.8 | -10.0 | -16.7 | 13.3 | -11.8 | 13.3 | −34.6% |
| 2012 | 0.0 | 100.0 | -5.6 | 2.9 | -2.9 | -11.8 | 0.0 | 13.3 | -8.8 | -9.7 | -21.4 | 18.2 | +44.4% |
| 2011 | 26.2 | -18.9 | -18.6 | -8.6 | 15.6 | -16.2 | 0.0 | -3.2 | -16.7 | -4.0 | -16.7 | -10.0 | −57.1% |
| 2010 | 0.0 | 13.2 | -18.6 | 0.0 | 2.9 | -8.3 | 12.1 | 5.4 | -15.4 | 0.0 | 15.2 | 10.5 | +10.5% |
| 2009 | 3.6 | -6.9 | 25.9 | 8.8 | 0.0 | -5.4 | 0.0 | 42.9 | 6.0 | 1.9 | -24.1 | -7.3 | +35.7% |
| 2008 | -13.3 | -11.1 | -14.4 | -21.3 | 7.1 | 2.7 | -9.1 | -5.7 | -9.1 | -31.7 | -19.5 | -15.2 | −79.3% |
| 2007 | 10.6 | 23.1 | 9.4 | 14.3 | -1.2 | 77.2 | -17.9 | -7.0 | -8.4 | 32.7 | 0.0 | 3.8 | +187.2% |
Buy / hold / sell counts
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
No recent headlines.